title: The evaluation of the role of CCK in the opioid modulation of the motility of the gastrointestinal tract in sheep.
abstract: The participation of central cholecystokinin-8 (CCK-8) receptors in the modulatory effect of D-Ala2, N-Me-Phe4, Gly5-ol enkephalin (DAGO), a selective mu-opioid receptor agonist, on the spike burst activity of the gastrointestinal tract (rumen, reticulum, antrum, duodenum, colon and caecum) in sheep was investigated. DAGO was infused intracerebroventricularly (i.c.v.) at doses of 0.1-1 microg/kg body weight (BW). It was shown that DAGO significantly inhibited myoelectrical activity of the wall of the forestomachs, abomasum and colon but stimulated this activity in the duodenum (rate of myoelectrical migrant complex-MMC). The effects of DAGO were prevented by CCK-8 antagonists (L-364.718 and L-365.260) previously infused at doses of 5-20 microg/kg BW. The results of this present study indicate that central receptors of CCK-8 participated in the modulatory action of an opioid on myoelectrical activity of the gastrointestinal tract in sheep. Furthermore, this result suggests that CCK-8 is released in response to mu-receptor stimulation, because CCK-8 antagonists (L-364.718 and L-365.260) prevented the modulatory action of DAGO on the gastrointestinal motility in sheep.
authors.affiliation: Department of Veterinary Pharmacology and Toxicology, Veterinary Faculty, Warsaw Agricultural University SGGW, Poland. wet_kfit@sggw.waw.pl
authors.forename: B F
authors.initials: BF
authors.lastname: Kania
authors.forename: P
authors.initials: P
authors.lastname: Brikas
authors.forename: L
authors.initials: L
authors.lastname: Buéno
authors.forename: J
authors.initials: J
authors.lastname: Fioramonti
authors.forename: M
authors.initials: M
authors.lastname: Zaremba-Rutkowska
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D002766:Cholecystokinin / Q000502:physiology*; D020109:Devazepide / Q000494:pharmacology; D004576:Electromyography; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007276:Injections, Intraventricular; D007422:Intestines / Q000187:drug effects; D009294:Narcotics / Q000494:pharmacology*; D010671:Phenylurea Compounds / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000187:drug effects / Q000502:physiology; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000502:physiology; D012756:Sheep; D013270:Stomach / Q000187:drug effects
chemical_list: D001570:Benzodiazepinones; D004745:Enkephalins; D009294:Narcotics; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C058121:L 365260; D002766:Cholecystokinin; D020109:Devazepide